Overview

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1®, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a second generation OVA1 test with significantly improved specificity and ease of use.

 

ASPiRA LABS, A Vermillion Company

ASPiRA LABs is a wholly-owned, specialized women’s health reference laboratory of Vermillion, Inc.  Its vision is to be the global leader in personalized medical management of gynecologic health to improve clinical outcomes for patients, physicians and payers.

You can trust the results that ASPiRA LABS provides and take comfort in the knowledge that OVA1® testing is FDA cleared and ASPiRA LABS is certified by Clinical Laboratory Improvement Amendments (CLIA), which means that we adhere to the highest standards in the clinical laboratory industry.  We pride ourselves on being at the forefront of women’s healthcare and ovarian cancer diagnosis.

We have a passion for assisting health care providers in the delivery of relevant and timely care to women. We believe our passion will become evident to you in the level of service that we provide.

 

ASPiRA IVD, A Vermillion Company

With most CROs focusing on pharma, biotech and medical device industries, IVD manufacturers are forced to deal with the larger commercial labs to provide testing in support of the IVD studies and trials.  But everything about a large commercial laboratory revolves around providing clinical testing for patients creating a range of problems/issues as patient testing takes priority over “research” testing for IVD trials and studies.

ASPiRA IVD was built for the sole purpose of meeting the needs of IVD manufacturers seeking to commercialize complex diagnostics.  Our custom solutions approach is designed to address the unique problems associated with IVD clinical trials and studies while streamlining the entire process from project estimates and contracting all the way through to the delivery of a locked study database.

To learn more about ASPiRA IVD and our offerings, please email [email protected].

 

Our vision is to be the global leader in personalized medical management of gynecologic health to improve clinical outcomes for patients, physicians and payers

Advocacy Partners

Aspira Labs supports and proactively partners with patient advocacy organizations to increase awareness of ovarian cancer detection.

For Women and Patients

Learn About Pelvic Masses, Wellness, and Ovarian Cancer

One out of five women will be diagnosed with a pelvic mass in her lifetime. We created KnowPelvicMass.com to educate women about the signs of a pelvic mass and how it relates to ovarian cancer. We also inspire women to be “in the know” about their wellness.